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Abstract 
Objective: This study assessed the association between glucose lowering drug (GLD) use, including metformin, 
sulphonylurea derivatives and insulin, after breast cancer diagnosis and breast cancer-specific and all-cause 
mortality.  
Methods: 1,763 breast cancer patients, diagnosed between 1998-2010, with type 2 diabetes were included. 
Cancer information was retrieved from English cancer registries, prescription data from the UK Clinical Practice 
Research Datalink and mortality data from the Office of National Statistics (up to January 2012). Time varying 
Cox regression models were used to calculate HRs and 95% CIs for the association between GLD use and breast 
cancer-specific and all-cause mortality. 
Results: In 1,057 patients with diabetes before breast cancer, there was some evidence that breast cancer-
specific mortality decreased with each year of metformin use (adjusted HR=0.88; 95%CI 0.75-1.04), with a 
strong association seen with over 2 years of use (adjusted HR=0.47; 95%CI:0.26-0.82). Sulphonylurea 
derivative use for less than 2 years was associated with increased breast cancer-specific mortality (adjusted 
HR=1.70; 95%CI:1.18-2.46) but longer use was not (adjusted HR=0.94; 95%CI: 0.54-1.66). In 706 patients who 
developed diabetes after breast cancer, similar patterns were seen for metformin but sulphonylurea derivative 
use was strongly associated with cancer-specific mortality (adjusted HR: 3.64; 95%CI:2.16-6.16), with similar 
estimates for short and long-term users.  
Conclusions: This study provides some support for an inverse association between, mainly long-term, 
metformin use and (breast cancer-specific) mortality. In addition, sulphonylurea derivative use was associated 
with increased breast cancer-specific mortality, but this should be interpreted cautiously, as it could reflect 
selective prescribing in advanced cancer patients. 
Key words: Glucose lowering drugs, metformin, sulphonylurea derivatives, insulin, diabetes, breast cancer,  
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Introduction 
Diabetes occurs in around 16% of  breast cancer patients[1,2] and is associated with a 40% increased breast 
cancer-specific[3] and a 50% increased all-cause mortality[4] . 
Metformin is currently used as primary treatment for Type 2 diabetes. If metformin monotherapy does not 
control hyperglycaemia sufficiently, sulphonylurea derivatives (SUs) or insulin may be added or switched to. 
Recently, metformin, has received much attention for its potential anti-tumour effects. Several laboratory studies 
show that metformin use is associated with cell growth suppression in breast cancer cells, possibly mediated by 
activation of 5’-adenosine monophosphate-activated protein kinase (AMPK)[5,6]. Observational studies also 
show that metformin use is associated with a 20-30% lower breast cancer incidence[7-9]. 
Four studies have investigated the association between metformin use and breast cancer-specific mortality or 
recurrence in breast cancer patients but reported conflicting results[10-13]. A 53% decreased breast cancer-
specific mortality was reported for metformin use versus non-use among human epidermal growth factor 
receptor 2 positive (HER2+) breast cancer patients[10] whereas the other studies did not find any 
association[13,11,12]. These studies had several limitations such as small sample size[12,13,10], no 
investigation of dose-response[12,13,10] and some were restricted to specific breast cancer subtypes (i.e. 
HER2+[10] or triple negative breast cancer[13]). Additionally, the study that reported a favourable effect for 
metformin might have been influenced by immortal time bias[14], as metformin users were classified as users 
from breast cancer diagnosis onwards, and not from the time of actual drug initiation[10]. Only one study used 
time dependent Cox regression analyses to avoid immortal time bias, but did not include lifestyle related 
covariates[11]. Conflicting results were also reported among studies that investigated the effect of Glucose 
Lowering Drugs (GLDs) on all-cause mortality[15,16]. One study reported no effect of metformin use prior or 
in the three months after breast cancer diagnosis on overall mortality[16], while another study did report a lower 
overall mortality among metformin users as compared to breast cancer patients without diabetes[15]. However, 
as these studies did not report on breast cancer-specific deaths, associations in these studies could reflect non-
cancer deaths[16,15]. Further research is needed to establish the effect of metformin and other GLDs on the 
prognosis of breast cancer patients with type 2 diabetes. 
Therefore, prompted by the promising preclinical evidence, our primary objective was to determine whether 
breast cancer patients with type 2 diabetes using metformin had reduced breast cancer-specific mortality and all-
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cause mortality. A secondary objective was to investigate the effect of other GLDs on breast cancer-specific and 
all-cause mortality.   
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Methods 
Data sources 
This retrospective cohort study used linked data from the Clinical Practice Research Datalink (CPRD), the 
National Cancer Data Repository (NCDR) and the Office of National Statistics (ONS). The CPRD contains 
demographical information, clinical diagnoses and prescription data for approximately 7% of the UK 
population[17]. The NCDR contains data on all cancer diagnoses in UK cancer registries including data on 
diagnosis date, site of primary cancer, stage, and treatment. Data regarding deaths were retrieved from the ONS 
registration which included breast cancer-specific (ICD codes C50.0 to C50.9) and all-cause mortality. The 
CPRD, NCDR and ONS death data were linked (using an algorithm based upon NHS number, gender, date of 
birth and postcode) for cancer patients in England. A multicentre research ethics committee gave ethical 
approval for all observational research using CPRD data.  
 
Study design 
A cohort of female breast cancer patients, diagnosed between 1998 and 2009, with type 2 diabetes was 
identified. Diabetes diagnosis was defined using previously validated clinical Read codes[18] or the first 
prescription of a GLD defined below, whichever occurred first. This study includes patients with diabetes prior 
to breast cancer (prevalent diabetes) as well as patients who developed diabetes after breast cancer diagnosis 
(incident diabetes). Patients with type 1 diabetes, which was defined as having a type 1 diabetes diagnosis code 
and a prescription of insulin prior to breast cancer diagnosis for prevalent diabetes patients and within 6 months 
after diabetes diagnosis for patients with incident diabetes, were excluded. Cancer patients with a previous 
cancer diagnosis were excluded, apart from in situ neoplasms and non-melanoma skin cancers. The index date 
was defined as date of breast cancer diagnosis for patients with prevalent diabetes and date of diabetes diagnosis 
for patients with incident diabetes. Patients were excluded if the index date occurred before they were registered 
at a CPRD practice, CPRD records at their general practice (GP) were of research quality or if the index date 
occurred after death or censoring. Patients who received hormone therapy more than 8 weeks prior their breast 
cancer diagnosis, or with diagnosed polycystic ovary syndrome were excluded. Follow-up started 6 months after 
the index date to remove deaths that occurred within this period, as it is unlikely that GLD medication use after 
diagnosis could influence such deaths. In the analysis of incident diabetes patients, the time since breast cancer 
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diagnosis remained the underlying time variable, Cox regression models were left-truncated with follow-up 
beginning 6 months after diabetes diagnosis. The patients were followed till death, the end of registration or last 
date of data collection of their GP or end of ONS follow up (10th of January 2012), whichever occurred first. 
 
Exposure to GLDs 
Exposure to metformin, SUs, other GLDs and insulin were identified using chapter 6.1 of the British National 
Formulary[19]. Days of exposure were calculated by dividing the prescribed quantity by the number of 
prescribed tablets/units per day. If the quantity or units per day was missing (<1% and <20% respectively), the 
most frequent quantity and the average daily dose per product was used. For insulin the units per day were not 
reported, so days of exposure was set to 60 days for each prescription. Cumulative days of exposure to all GLDs 
were calculated in 30 day intervals.  
 
Covariates 
Cancer stage and treatment (surgery, radiotherapy and chemotherapy) within the six months after breast cancer 
diagnosis were retrieved from the NCDR. Hormone treatment (including tamoxifen and aromatase inhibitor use) 
in the six months after breast cancer diagnosis was derived from GP prescription records. Smoking and Body 
Mass Index (BMI) closest to the index date were determined from the GP records; records more than 5 years 
prior to the index date were ignored. Comorbidities prior to the index date were identified using clinical Read 
codes which were previously validated with an adapted version of the Charlson comorbidity index[18]. The use 
of Hormone Replacement Therapy (HRT), low-dose aspirin and statin prior to the index date were retrieved 
from the GP records. HbA1c measures in % according to the National Glycohemoglobin Standardization 
Program (NGSP) were retrieved for the year prior to breast cancer diagnosis for prevalent diabetes patients and 
between 6 months prior and 6 months after diabetes diagnosis for incident diabetes patients. The HbA1c 
measurement closest to the index date was used in the analyses. 
 
Statistical analyses 
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The main analyses used time dependent Cox regression models with time to breast cancer-specific deaths and 
all-cause mortality as the outcome, where metformin, SU, other GLDs and insulin use were modelled as time 
varying covariates. A 6 months lag was used, which removes all GLD prescriptions in the 6 months prior to the 
end of study or death (i.e. as medication use in these months might reflect end of life treatment), as previously 
recommended[20]. Exposure to GLDs was modelled using time varying ever/never terms (i.e. patients are 
classified as unexposed until 6 months after first drug prescription and as exposed afterwards). In addition, a 
linear trend was fitted to assess per year exposure to GLDs, time-varying terms for year of exposure to GLDs, 
with time varying ever/never terms were included in the model as recommended [21]. Moreover short and long-
term exposure was modelled using categories (<2 years of exposure and ≥2 years of exposure). Hazard ratios 
(HR) and 95% confidence intervals (95%CIs) were reported.  
An unadjusted model was constructed and included use of metformin, SU, other GLDs and insulin use. The 
fully adjusted model included the following covariates which were available for the entire cohort: age at breast 
cancer diagnosis, calendar year of breast cancer diagnosis, diabetes duration for prevalent diabetes patients, 
breast cancer treatment within 6 months (i.e. dichotomous covariates for surgery, chemotherapy, radiotherapy 
and hormone therapy), the use of HRT prior to breast cancer diagnosis, and comorbidities prior to the study start 
(including stroke, chronic pulmonary disease, congestive heart disease, diabetes with complications, myocardial 
infarction, peptic ulcer disease, peripheral vascular disease and renal disease).  
Several sensitivity analyses based on the fully adjusted time varying ever/never analysis were conducted and 
include additional adjustments for BMI, smoking, stage and HbA1c measures. A sensitivity analysis restricted to 
patients who had a follow-up >1 year in which the lag was increased to 1 year was performed. Among prevalent 
diabetes patients, a simplified Cox regression analyses was performed comparing GLD use to non-use in the 6 
months after diagnosis, removing the need for time varying covariates. Moreover, among prevalent diabetes 
patients, a nested case cohort analysis was performed. Cases who died of breast cancer were matched on age (5 
year intervals) and year of cancer diagnosis (2 year intervals) to up to 10 controls within the cohort who lived at 
least as long after diagnosis as their matched case. The exposure period was defined as the period from breast 
cancer diagnosis till 6 months prior to death for cases and a period of identical duration from breast cancer 
diagnosis was defined for the matched controls. Metformin, SU, insulin and other GLD use was determined in 
the exposure period. Conditional logistic regression was used to calculate odds ratios (OR) and 95%CIs. All 
statistical analyses were performed using STATA 13 (College Station, TX).  
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Results 
Study population 
1,057 patients with prevalent diabetes at breast cancer diagnosis and 706 patients with incident diabetes were 
included (Figure 1). The mean age of prevalent diabetes patients was 70.6 (SD=11.3) years at breast cancer 
diagnosis and they were diagnosed with diabetes on average 6.6 (SD=6.0) years prior (Table 1). During follow-
up, metformin was used by 65%, SUs by 50%, insulin by 21% and other GLDs by 21% of the prevalent diabetes 
patients. 189 (18%) prevalent diabetes patients used no GLDs, 332 (31%) used 1 GLD and 536 (51%) used a 
combination of ≥2 GLDs. The most frequent used combinations were metformin and SUs (n=205, 19%), 
metformin monotherapy (n=187, 18%), and metformin, SUs and other GLDs (n=105, 10%).  Patients who did 
not use GLDs or who used SUs during follow-up were leaner than other groups e.g. 29% and 16% had a BMI 
<25 kg/m2, respectively, compared with 11% among metformin and insulin users. Insulin users had more 
complications (25%) than other groups and had the highest HbA1c levels (mean=8.2, SD=1.8 %NGSP). Mean 
follow-up time from breast cancer diagnosis was 4.4 years (SD=2.9 years, maximum 13.8 years) and a total of 
348 prevalent diabetes patients died (150 were breast cancer-specific deaths). 
Incident diabetes patients were on average 64.4 (SD=11.4) years at breast cancer diagnosis and were diagnosed 
with diabetes on average 3.3 (SD=2.6) years after breast cancer diagnosis (Table 1). Metformin use was similar 
compared to prevalent diabetes patients (62% versus 65% using metformin during follow-up) but SU use, 
insulin and other GLDs was lower with 30%, 5% and 10% versus 50%, 21% and 21%, respectively. 224 (32%) 
incident diabetes patients used no GLDs, 278 (39%) used 1 GLD and 204 (29%) used a combination of ≥2 
GLDs. The most frequent used combinations were metformin monotherapy (n=235, 33%), metformin and SUs 
(n=115, 16%), and metformin, SUs and other GLDs (n=37, 5%). Metformin and other GLD users had the 
highest BMIs with respectively, 47% and 50% being obese as compared to 37% and 29% for SU and insulin 
users, respectively. HbA1c levels were highest among insulin users with an average of 8.2 %NGSP. Mean 
follow-up from diabetes diagnosis was 3.9 years (SD=2.7 years, and maximum 13.0 years) and a total of 134 
patients died (68 were breast cancer-specific deaths).  
 
The association between GLD use and mortality 
Breast cancer patients with prevalent diabetes 
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Breast cancer-specific mortality rates were lower in metformin users compared with non-users (HR=0.64; 
95%CI:0.46-0.91), although this was attenuated after adjustment for potential confounders (adjusted HR=0.78; 
95%CI:0.55-1.12) (Table 2).  The majority of this attenuation could be explained by adjustment for age and year 
of  breast cancer diagnosis (HR adjusted for age and year of diagnosis=0.79; 95%CI:0.55-1.12). Sensitivity 
analyses showed that adjustment for stage further attenuated the effect of metformin (HR=0.96; 95%CI:0.53-
1.75) while increasing the lag to 1 year and the case control analysis showed similar results (Table 4). The 
association was not observed per year of metformin use (unadjusted HR=0.88; 95%CI:0.75-1.04, adjusted 
HR=0.88; 95%CI:0.75-1.04) (Table 2). A more marked association with breast cancer-specific mortality was 
observed among individuals using metformin for ≥2 years (adjusted HR=0.47; 95%CI:0.26-0.82), rather than 
for shorter periods (adjusted HR=0.88; 95%CI:0.61-1.27). In sensitivity analyses the association between 
metformin use for ≥2 years was attenuated slightly after adjustment for BMI (HR=0.53; 95%CI:0.28-1.00), or 
after increasing the lag to 1 year (HR=0.54; 95%CI:0.30-1.00). Adjustment for stage at diagnosis (available for 
39 percent of cases) further attenuated this association (HR=0.62; 95%CI:0.25-1.55) (data not shown). 
Breast cancer-specific mortality was increased in SU users compared with non-users (HR=1.56; 95%CI=1.11-
2.19), but attenuated after adjustments (HR=1.41; 95%CI=1.00-1.99). As before, the majority of this attenuation 
could be explained by adjustment for age and year of breast cancer diagnosis (HR adjusted for age and year of 
diagnosis=1.37; 95%CI:0.97-1.93). Sensitivity analysis showed that adjustments for BMI and smoking further 
attenuated the association; HR=1.36; 95%CI:0.94-1.99 and HR=1.27; 95%CI:0.86-1.89 respectively (data not 
shown). Additional adjustments for stage resulted in a slightly higher hazard ratio for SU use (HR =1.76; 
95%CI:0.99-1.34), but the case control analysis showed similar results (Table 4). No significant association was 
seen per year increase in sulphonlyurea derivative use (unadjusted HR=0.96; 95%CI:0.81-1.14 and adjusted 
HR=0.96; 95%CI:0.81-1.15, Table 2). Further analysis revealed that SU use for <2 years was associated with an 
increase in breast cancer-specific mortality (HR=1.70; 95%CI:1.18-2.46) whereas longer use (≥2 years) was not 
(HR=0.94; 95%CI:0.54-1.66). A similar pattern was seen for insulin users, although based on smaller numbers. 
There was little evidence of an association between use of other GLDs and breast cancer-specific mortality. 
 
Breast cancer patients with incident diabetes  
No association between breast cancer-specific mortality and metformin use was seen among breast cancer 
patients with incident diabetes (unadjusted HR=0.97; 95%CI:0.58-1.71, adjusted HR=0.99; 95%CI=0.58-1.71). 
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However, cumulative exposure to metformin was associated with breast-cancer specific mortality (HR=0.73; 
95%CI:0.56-0.95), and this effect remained after adjustments (HR=0.73; 95%CI:0.56-0.96). Although not 
significant, similar patterns to those with prevalent diabetes were observed for ≥2 years metformin use (Table 
3).  
Ever versus never use of SUs was associated with substantially higher breast cancer-specific mortality 
(unadjusted HR=3.41; 95%CI:2.07-5.64 and adjusted HR= 3.15; 95%CI:1.87-5.30). Additional adjustment for 
stage and the use of a 1 year lag slightly attenuated the association but this effect remained significant (Table 4). 
No association between breast cancer-specific mortality and cumulative SU exposure per year was observed 
(adjusted HR=0.88; 95%CI:0.66-1.16) (Table 3). Both <2 years and ≥2 years SU use was associated with higher 
breast cancer-specific mortality; HR=3.51 (95%CI:2.04-6.06) and HR=3.51 (95%CI:1.31-9.36), respectively. 
The low number of incident diabetes patients using insulin or other GLDs hampered the calculation of reliable 
estimates of mortality risk. 
For both prevalent and incident diabetes patients, additional adjustments for statin and aspirin use prior to breast 
cancer diagnosis did not materially affect observed associations between GLD use and breast cancer-specific 
mortality (data not shown). Analysis of all-cause mortality, also shown in Table 2 and 3, displayed similar 
patterns to the breast cancer-specific analyses. 
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Discussion 
This study showed some evidence of lower breast cancer-specific and all-cause mortality rates in breast cancer 
patients with diabetes who were treated with metformin, especially among longer term users (≥2 years 
exposure), but these associations were attenuated in sensitivity analyses. In contrast, SU use was associated with 
substantially increased breast cancer-specific and all-cause mortality, however there was no dose response 
association, these associations were most marked in short-term users, and in patients who developed diabetes 
after their breast cancer diagnosis. 
Only one previous study[11] has provided data relating to the potential effects of metformin, SUs, insulin and 
other GLDs on breast cancer-specific mortality, and adjusted for the use of other GLDs. This study, revealed no 
significant association between metformin use and mortality[11]. However, we observed some evidence of an 
association for long-term use of metformin on mortality. Also, Lega et al. did not find an association between 
SU use versus non-use and breast cancer-specific (HR=0.97; 95%CI:0.86-1.16) or all-cause mortality 
(HR=0.98; 95%CI:0.94-1.04), nor for SU use modelled per year of exposure[11]. In contrast, we observed an 
increased breast cancer-specific and all-cause mortality for short-term SU use among those with prevalent 
diabetes at breast cancer diagnosis. Among those with incident diabetes we found a more pronounced increased 
mortality among SU users in all analyses. Lega et al did not assess short and long-term SU use and they did not 
include patients who developed diabetes after their breast cancer diagnosis[11].  
The observed reduction in cancer-specific mortality in longer-term metformin users is consistent with findings 
from preclinical studies suggesting that metformin may have anti-tumour properties. Metformin may directly 
supress breast cancer cell growth via activation of the AMP-activated protein kinase, resulting in downstream 
signalling of the protein kinase, MTOR, which regulates cell growth[22,23]. Moreover, due to the activation of 
the AMP-activated protein kinase and inhibition of MTOR, metformin might act synergistically with 
chemotherapeutic agents[24], and positively influence response to adjuvant chemotherapy in diabetic breast 
cancer patients[25]. Metformin may also work through an indirect mechanism by improving insulin sensitivity, 
thereby reducing insulin levels[26], and decreasing activation of IGF-1 receptors [27]. Deactivation of IGF-1 
may inhibit Cyr61, and thereby suppress breast cancer growth and invasion[28]. On the other hand, the observed 
reduction in breast cancer-specific mortality rates in metformin users could also be due to residual confounding 
or reflect chance, particularly as the association was most apparent among long-term users of metformin. 
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Further evidence will be provided by an ongoing randomised controlled trial of metformin versus placebo in 
over 3,500 women with breast cancer, although results will not be reported until the end of 2016[29,30].  
Previous studies reported increased mortality rates in cancer patients using SUs but of less magnitude than 
associations seen in our study[31,16]. We believe that the increased cancer-specific mortality in SU users 
apparent in our data should be interpreted cautiously for various reasons. First, we did not have a prior 
hypothesis regarding the association between SUs and mortality. Second, the association with SUs did not 
follow a dose response, which is counterintuitive. Third, although strong associations were seen in those with 
incident diabetes the risk estimates were based on small numbers of deaths. Fourth, a proportion of the diabetes 
occurring after a breast cancer diagnosis might partly be due to treatment for advanced/recurrent disease (e.g. 
steroids), which is often a transient condition. Finally, in patients with advanced cancer it has been 
recommended that SUs are used in preference to metformin due to the gastro-intestinal side effects of 
metformin[32], consequently  these drugs may be spuriously associated with increased cancer-specific 
mortality. 
From a physiological point of view, it is possible that SUs detrimentally affect breast cancer 
progression/metastasis, possibly mediated through hyperinsulinemia, as SUs increase insulin secretion[33] and 
preclinical studies have shown that hyperinsulinemia may promote breast cancer metastasis to the lung[34]. 
Moreover, observational studies have shown that hyperinsulinemia is associated with increased cancer-specific 
mortality[35]. Despite the caveats mentioned above, the associations we have seen between SU use and 
mortality in breast cancer patients are worthy of further investigation. 
This study used data from a large population-based database which is of validated high quality[17,18]. 
Importantly, time dependent analyses were performed to avoid immortal time bias[14], we accounted for 
cumulative exposure to GLDs, and conducted sensitivity analyses to investigate the robustness of our findings. 
In addition, GLDs are not available ‘over the counter’ in the UK, so it is likely that we captured all GLD use in 
our study, apart perhaps from use during care within hospital or a hospice. However, this study also has several 
limitations. We do not have data on patients’ compliance with prescribed medications. Cancer stage at diagnosis 
was missing in 60% of our study population, although stage distribution appeared similar in metformin users 
and non-users. Additional adjustments for stage attenuated observed hazard ratios but this appeared to result 
from the restriction of the dataset to those with available stage, rather than an effect of adjustment for stage per 
se. We did not have data on disease progression while GLD use may have changed following cancer recurrence, 
13 
 
although associated biases should be reduced in lagged analyses. Moreover, there may have been some 
misclassification regarding the cause of death.  
In conclusion, this study provides some support for an inverse association between metformin exposure and 
(breast cancer-specific) mortality among breast cancer patients. In addition, an increased breast cancer-specific 
mortality was observed among SU users. This finding should be interpreted cautiously, as it could reflect 
selective prescribing in advanced cancer patients, but merits further investigation. 
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Figure 1 Patient selection 
 
34,875 women were diagnosed with 
primary breast cancer between  
1998‐2010 
3,086 (9%) women were diagnosed with 
breast cancer and diabetes type 2 
31,789 were not diagnosed with 
diabetes type 2 
1,763 patients with diabetes and breast 
cancer diagnosis were included 
1,323 excluded, because: 
- Index date after the end of follow‐
up (n=282) 
- Index date preceded CPRD quality 
records (n=775) 
- Treatment with hormone therapy 
more than 2 months prior to breast 
cancer diagnosis (n=65) 
- Diagnosis of Polycystic Ovary 
Syndrome (n=1) 
- No death data or died within half a 
year after index date (n=200) 
706 developed diabetes after breast 
cancer diagnosis (incident diabetes) 
1057 had diabetes at breast cancer 
diagnosis (prevalent diabetes) 
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aValues reported are means and sd. 
Table 1 Descriptives of the study population including patients with prevalent diabetes at breast cancer diagnosis and incident diabetes after breast cancer diagnosis 
 Prevalent diabetes (n=1,057) Incident diabetes (n=706) 
 Total 
 
Metformin  SU  
 
Insulin  Other GLDs No GLD 
use 
Total 
 
Metformin  SU  
 
Insulin  Other GLDs No GLD 
use 
N(%) 1057 (100) 688 (65) 528 (50) 220 (21) 220 (21) 189 (18) 706 (100) 437 (62) 210 (30) 35 (5) 74 (10) 224 (32) 
Age at BC diagnosis (yrs) a 70.6 (11.3) 68.6 (11.0) 70.6 (11.2) 66.9 (10.6) 66.2 (10.5) 74.4 (11.1) 64.4 (11.4) 62.1 (10.7) 64.6 (10.8) 61.6 (11.4) 60.9 (8.8) 67.7 (11.4) 
BMI (kg/m2)             
< 25 kg/m2 172 (16) 77 (11) 85 (16) 25 (11) 18 (8) 54 (29) 55 (8) 26 (6) 14 (7) 4 (11) 3 (4) 26 (12) 
25 – 30 kg/m2  325 (31) 219 (32) 175 (33) 66 (30) 63 (29) 52 (28) 164 (23) 84 (19) 41 (20) 8 (23) 14 (19) 67 (30) 
≥30 kg/m2 456 (43) 338 (49) 216 (41) 111 (50) 124 (56) 62 (33) 280 (40) 204 (47) 78 (37) 10 (29) 37 (50) 66 (29) 
Missing 104 (10) 54 (8) 52 (10) 18 (8) 15 (7) 21 (11) 207 (30) 123 (28) 77 (37) 13 (37) 20 (27) 65 (29) 
Smoking status              
Never 570 (54) 373 (54) 289 (55) 119 (54) 118 (54) 103 (55) 345 (49) 200 (46) 90 (43) 14 (40) 29 (39) 126 (56) 
Ever 368 (35) 247 (36) 169 (32) 78 (35) 79 (36) 66 (35) 250 (35) 164 (38) 76 (36) 16 (46) 31 (42) 71 (32) 
Missing 119 (11) 68 (10) 70 (13) 23 (10) 23 (10) 20 (11) 111 (16) 73 (17) 44 (21) 5 (14) 14 (19) 27 (12) 
Comorbidities              
Diabetes with complications 131 (12) 82(12) 63 (12) 56 (25) 28 (13) 13 (7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Stroke 109 (10) 61 (9) 58 (11) 25 (11) 20 (9) 21 (11) 40 (6) 16 (4) 9 (4) 2 (6) 1 (1) 21 (9) 
Chronic pulmonary disease 209 (20) 138 (20) 102 (19) 36 (16) 52 (24) 37 (20) 139 (20) 89 (20) 41 (20) 8 (23) 18 (24) 41 (18) 
Heart disease 163 (15) 82 (12) 75 (14) 41 (19) 23 (10) 33 (17) 64 (9) 34 (8) 21 (10) 2 (6) 5 (7) 23 (10) 
Time between diabetes and breast 
cancer diagnosis (yrs) a 
6.6 (6.0) 6.4 (5.4) 6.9 (5.8) 10.0 (6.9) 6.7 (5.0) 5.1 (6.0) - - - - - - 
Time between breast cancer and 
diabetes diagnosis (yrs) a 
- - - - - - 3.3 (2.6) 3.1 (2.5) 2.7 (2.4) 2.4 (2.1) 2.6 (1.9) 3.9 (2.9) 
HbA1c (%NGSP) a 7.2 (1.4) 7.4 (1.4) 7.5 (1.5) 8.2 (1.8) 7.6 (1.4) 6.1 (0.7) 7.2 (1.4) 7.5 (1.6) 7.9 (1.7) 8.2 (2.3) 7.9 (1.7) 6.5 (4.9) 
GLD use after BC diagnosis              
Metformin 688 (65) 688 (100) 397(75) 157 (71) 193 (88) - 437 (62) 437 (100) 172 (82) 28 (80) 72 (97) - 
Sulphonylurea derivatives 528 (50) 397 (58) 528 (100) 101 (46) 167 (76) - 210 (30) 172 (39) 210 (100) 22 (63) 47 (64) - 
Insulin 220 (21) 157 (23) 101 (19) 220 (100) 60 (28) - 35 (5) 28 (6) 22 (10) 35 (100) 13 (18) - 
Other GLDs 220 (21) 193 (28) 167 (32) 60 (27) 220 (100) - 74 (10) 72 (16) 47 (22) 13 (37) 74 (100) - 
No GLDs 189 (18) - - - - 189 (100) 224 (32) - - - - 224(100) 
Cancer stage             
I 167(16) 109 (16) 81 (15) 41 (19) 40 (18) 32 (17) 140 (20) 89 (20) 30 (14) 2 (6) 10 (14) 46 (21) 
II 186 (18) 131 (19) 100 (19) 42 (19) 44 (20) 27 (14) 175 (25) 120 (27) 61 (29) 15 (43) 20 (27) 41 (18) 
III 43 (4) 26 (4) 22 (4) 8 (4) 8 (4) 9 (5) 24 (3) 10 (2) 6 (3) 3 (9) 2 (3) 12 (5) 
IV 14 (1) 6 (1) 4 (1) 2 (1) 1 (0) 5 (3) 9 (1) 4 (1) 6 (3) 0 (0) 0 (0) 2 (1) 
Missing 647 (61) 416 (60) 321 (61) 127 (58) 127 (58) 116 (61) 358 (51) 214 (49) 107 (51) 15 (43) 42 (57) 123 (55) 
Cancer treatment in 6 months 
after BC diagnosis 
            
Surgery 817 (77) 561 (82) 413 (78) 172 (78) 188 (85) 139 (74) 626 (89) 399 (91) 190 (90) 34 (97) 70 (95) 190 (85) 
Chemotherapy  152 (14) 118 (17) 76 (14) 39 (18) 42 (19) 14 (7) 163 (23) 119 (27) 64 (30) 15 (43) 21 (28) 32 (14) 
Radiotherapy 419 (40) 305 (44) 209 (40) 97 (44) 104 (47) 58 (31) 337 (48) 225 (51) 103 (49) 14 (40) 40 (54) 97 (43) 
Hormone treatment 821 (78) 520 (76) 415 (79) 166 (75) 156 (71) 155 (82) 516 (73) 302 (69) 153 (73) 23 (67) 50 (68) 175 (78) 
HRT before BC diagnosis 284 (27) 205 (30) 136 (26) 84 (38) 80 (36) 43 (23) 240 (34) 153 (35) 61 (29) 17 (49) 30 (41) 75 (33) 
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Table 2 The association between GLD use and breast cancer-specific and all-cause mortality among breast cancer patients with prevalent diabetes. 
a Model includes ever vs. never exposure to metformin, sulphonylurea derivatives (SU), insulin and other GLDs  
b Model includes cumulative exposure to metformin, SU, insulin and other GLDs per year and is additionally adjusted for ever vs. never exposure to metformin, SU, insulin and other GLDs 
c Model is adjusted for age at BC diagnosis, diabetes duration (years) before BC, year of BC diagnosis, BC treatment (surgery, radiotherapy, chemotherapy, hormone therapy within 6 months 
after BC diagnosis), hormone replacement therapy prior to BC diagnosis (yes/no), comorbidity (stroke, chronic pulmonary disease, congestive heart disease, diabetes with complications, 
myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease) prior to BC diagnosis (yes/no) 
*P-value<0.05  
 
Nos. of 
BC /all 
deaths 
Nos. 
of 
patients 
Person 
years 
Unadjusted analyses Adjusted analyses 
Ever vs. never a Per year of use b Ever vs. never a,c Per year of use b,c <2 years use versus none c 
>2 years use versus 
none c 
HR (95% CI) HR (95% CI) HR (95%CI) HR (95%CI) HR (95%CI) HR (95%CI) 
Breast cancer-specific mortality
Metformin          
Yes 77 688 2,512 0.64 (0.46-0.91)* 0.88 (0.75-1.04) 0.78 (0.55-1.12) 0.88 (0.75-1.04) 0.88 (0.61-1.27) 0.47 (0.26-0.82)* 
No 73 369 1,612       
SU          
Yes 78 528 1,839 1.56 (1.11-2.19)* 0.96 (0.81-1.14) 1.41 (1.00-1.99) 0.96 (0.81-1.15) 1.70 (1.18-2.46)* 0.94 (0.54-1.66) 
No 72 529 2,286       
Insulin          
Yes 29 220 733 1.25 (0.82-1.89) 1.03 (0.84-1.26) 1.37 (0.87-2.14) 1.04 (0.85-1.28) 1.63 (0.99-2.68) 1.05 (0.51-2.18) 
No 121 837 3,391       
Other GLDs          
Yes 25 220 705 1.00 (0.63-1.57) 0.96 (0.73-1.25) 1.12 (0.70-1.78) 0.92 (0.70-1.21) 1.26 (0.76-2.08) 1.10 (0.48-2.52) 
No 125 837 3,419       
All-cause mortality 
Metformin          
Yes 174 688 2,512 0.62 (0.50-0.78)* 0.91 (0.82-1.01) 0.85 (0.67-1.07) 0.93 (0.84-1.03) 0.90 (0.70-1.16) 0.70 (0.49-0.99)* 
No 174 369 1,612       
SU          
Yes 175 528 1,839 1.51 (1.21-1.89)* 0.92 (0.83-1.02) 1.26 (1.01-1.58)* 0.89 (0.79-0.99)* 1.49 (1.17-1.91)* 0.85 (0.59-1.22) 
No 173 529 2,286       
Insulin          
Yes 65 220 733 1.20 (0.91-1.58) 0.92 (0.81-1.06) 1.35 (1.00-1.81) 0.95 (0.83-1.09) 1.57 (1.13-2.18)* 1.00 (0.60-1.65) 
No 283 837 3,391       
Other GLDs          
Yes 47 220 705 0.77 (0.56-1.06) 0.94 (0.78-1.13) 0.95 (0.68-1.31) 0.91 (0.75-1.10) 1.00 (0.69-1.46) 0.93 (0.53-1.62) 
No 301 837 3,419       
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Table 3 The association between GLD use and breast cancer-specific and all-cause mortality among breast cancer patients with incident diabetes. 
a Model includes ever vs. never exposure to metformin, sulphonylurea derivatives (SU), insulin and other GLDs  
b Model includes cumulative exposure to metformin, SU, insulin and other GLDs per year and is additionally adjusted for ever vs. never exposure to metformin, SU, insulin and other GLDs 
c Model is additionally adjusted for age at BC diagnosis, year of BC diagnosis, BC treatment (surgery, radiotherapy, chemotherapy, hormone therapy within 6 months after BC diagnosis), 
hormone replacement therapy prior to BC diagnosis (yes/no), comorbidity (stroke, chronic pulmonary disease, congestive heart disease, myocardial infarction, peptic ulcer disease, peripheral 
vascular disease, renal disease) prior to BC diagnosis (yes/no) 
*P-value<0.05 
  
 
Nos. of 
BC /all 
deaths 
Nos. 
of 
patients 
Person 
years 
Unadjusted analyses  Adjusted analyses 
Ever vs. never a Per year of use b  Ever vs. never a,c Per year of use b,c <2 years use versus none c 
>2 years use versus 
none c 
HR (95% CI) HR (95% CI)  HR (95%CI) HR (95%CI) HR (95%CI) HR (95%CI) 
Breast cancer-specific mortality
Metformin           
Yes 40 437 1,363 0.97 (0.58-1.64) 0.73 (0.56-0.95)*  0.99 (0.58-1.71) 0.73 (0.56-0.96)* 1.17 (0.68-2.03) 0.47 (0.17-1.27) 
No 28 269 1,063        
SU           
Yes 33 210 578 3.41 (2.07-5.64)* 0.85 (0.65-1.12)  3.15 (1.87-5.30)* 0.88 (0.66-1.16) 3.51 (2.04-6.06)* 3.51 (1.31-9.36)* 
No 35 496 1,848        
Insulin           
Yes 3 35 88 0.98 (0.30-3.23) 0.60 (0.15-2.45)  0.93 (0.27-3.20) 0.62 (0.15-2.53) 1.15 (0.32-4.19) - 
No 65 671 2,338        
Other GLDs           
Yes 4 74 232 0.42 (0.14-1.23) 1.94 (1.01-3.70)*  0.40 (0.13-1.17) 1.52 (0.78-2.95) 0.35 (0.08-1.49) 0.61 (0.13-2.91) 
No 64 632 2,194        
All-cause mortality 
Metformin           
Yes 69 437 1,363 0.70 (0.48-1.01) 1.03 (0.89-1.19)  0.79 (0.54-1.17) 1.04 (0.90-1.21) 0.81 (0.54-1.22) 0.66 (0.37-1.19) 
No 65 269 1,063        
SU           
Yes 56 210 578 2.71 (1.88-3.92)* 1.01 (0.85-1.19)  2.50 (1.71-3.66)* 0.98 (0.83-1.16) 2.60 (1.73-3.91)* 2.15 (1.11-4.16)* 
No 78 496 1,848        
Insulin           
Yes 7 35 88 1.33 (0.60-2.95) 0.61 (0.28-1.33)  1.41 (0.61-3.23) 0.66 (0.31-1.42) 1.69 (0.68-4.20) 0.68 (0.09-5.13) 
No 127 671 2,338        
Other GLDs           
Yes 9 74 232 0.51 (0.25-1.07) 0.99 (0.61-1.59)  0.53 (0.25-1.11) 0.90 (0.56-1.44) 0.62 (0.27-1.42) 0.31 (0.07-1.39) 
No 125 632 2,194        
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Table 4 Sensitivity analyses assessing the association between GLD use and breast cancer-specific mortality among prevalent and incident diabetes patients 
a Model includes exposure to metformin, sulphonylurea derivatives (SUs), insulin and other GLDs and are additionally adjusted for age at BC diagnosis, diabetes duration (years) before BC, 
year of BC diagnosis, BC treatment (surgery, radiotherapy, chemotherapy, hormone therapy within 6 months after BC diagnosis), hormone replacement therapy prior to BC diagnosis (yes/no), 
comorbidity (stroke, chronic pulmonary disease, congestive heart disease, diabetes with complications, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease) 
prior to BC diagnosis (yes/no) 
b Exposure to metformin, SUs, insulin and other GLDs were modelled as time varying covariates, where patients become exposed after the first prescription of the respective drug (i.e. 
ever/never analysis) 
c Model includes exposure to metformin, SUs, insulin and other GLDs and are additionally adjusted for age at BC diagnosis, year of BC diagnosis, BC treatment (surgery, radiotherapy, 
chemotherapy, hormone therapy within 6 months after BC diagnosis), hormone replacement therapy prior to BC diagnosis (yes/no), comorbidity (stroke, chronic pulmonary disease, congestive 
heart disease, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease) prior to BC diagnosis (yes/no) 
d OR and 95% CIs presented. Among cases (n=149), 76 (51%) used metformin, 77 (52%) used SUs, 28 (19%) used insulin and 24 (16%) used other GLDs. Among controls (n=1373), 752 
(55%) used metformin, 587 (43%) used SUs, 201 (15%) used insulin and 189 (14%) used other GLDs. 
 
 
   Metformin SU Insulin Other GLDs 
 Nos. of 
BC deaths 
Nos. of 
patients 
Ever versus never 
HR (95%CI) 
Ever versus never 
HR (95%CI) 
Ever versus never 
HR (95%CI) 
Ever versus never 
HR (95%CI) 
Prevalent diabetes patients (n=1057)        
Main ever never analysis (Table 2) a,b 150 1057 0.78 (0.55-1.12) 1.41 (1.00-1.99) 1.37 (0.87-2.14) 1.12 (0.70-1.78) 
Analysis in patients with available stage  a,b 57 410 0.90 (0.52-1.55) 1.38 (0.80-2.40) 1.01 (0.50-2.04) 1.25 (0.62-2.50) 
Additionally adjusted for stage  a,b 57 410 0.96 (0.53-1.75) 1.76 (0.99-3.14) 1.33 (0.61-2.90) 1.44 (0.69-2.97) 
Used a lag of 1 year instead of 6 months  a,b 132 987 0.76 (0.52-1.12) 1.23 (0.85-1.78) 1.70 (1.06-2.72) 1.38 (0.85-2.24) 
Use of GLDs in 6 months after BC diagnosis  
(not time varying) a 
150 1057 0.75 (0.53-1.07) 1.28 (0.91-1.81) 1.07 (0.60-1.91) 1.40 (0.80-2.42) 
Case control analysis a,d  1522 0.78 (0.53-1.15) 1.41 (0.98-2.04) 1.35 (0.81-2.25) 1.07 (0.63-1.81) 
       
Incident diabetes patients (n=706)        
Main ever never analysis (Table 3) b,c 68 706 0.99 (0.58-1.71) 3.15 (1.87-5.30) 0.93 (0.27-3.20) 0.40 (0.13-1.17) 
Analysis in patients with available stage b,c 38 348 0.87 (0.41-1.83) 3.72 (1.84-7.51) 0.97 (0.13-7.41) 0.18 (0.02-1.37) 
Additionally adjusted for stage b,c 38 348 0.93 (0.45-1.95) 2.80 (1.34-5.87) 0.56 (0.06-5.37) 0.18 (0.02-1.39) 
Used a lag of 1 year instead of 6 months b,c 53 623 1.19 (0.65-2.20) 2.88 (1.60-5.20) 1.30 (0.36-4.72) 0.32 (0.09-1.14) 
